Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AFINITOR DISPERZ vs BEYFORTUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Everolimus is an m TOR inhibitor that binds to FKBP-12, forming a complex that inhibits the m TOR serine-threonine kinase, thereby blocking cell cycle progression, angiogenesis, and cell growth.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.
Advanced hormone receptor-positive, HER2-negative breast cancer (postmenopausal women, in combination with exemestane),Advanced neuroendocrine tumors of pancreatic origin (unresectable, locally advanced, or metastatic),Advanced neuroendocrine tumors of gastrointestinal or lung origin (unresectable, locally advanced, or metastatic),Renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery,Subependymal giant cell astrocytoma (SEGA) associated with TSC,Renal cell carcinoma (advanced, after failure of sunitinib or sorafenib),Prevention of organ rejection in renal and cardiac transplant recipients (off-label: liver transplant)
Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season, and in children up to 24 months of age who remain vulnerable through their second RSV season.
10 mg orally once daily for advanced hormone receptor-positive, HER2-negative breast cancer; 10 mg orally once daily for advanced pancreatic neuroendocrine tumors; 10 mg orally once daily for advanced renal cell carcinoma; 7.5 mg orally once daily for subependymal giant cell astrocytoma (SEGA); 5 mg orally once daily for tuberous sclerosis complex (TSC)-associated renal angiomyolipoma.
Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.
Terminal half-life is approximately 30 hours (range 28-35 hours) in patients with advanced solid tumors, supporting once-daily dosing.
Terminal elimination half-life is approximately 26.8 days in infants, supporting season-long protection after a single dose.
Everolimus is metabolized primarily by CYP3A4 and is a substrate of P-glycoprotein (P-gp). It is also a moderate inhibitor of CYP3A4 and P-gp.
Nirsevimab is degraded via catabolic pathways into small peptides and amino acids.
Primarily fecal (80%) with 22% as unchanged drug; renal excretion <5%.
Beyfortus (nirsevimab) is eliminated primarily via catabolism to small peptides and amino acids. No specific data on renal or biliary excretion; expected to undergo proteolytic degradation with minimal renal or fecal elimination of intact drug.
Approximately 74% bound to plasma proteins (mainly albumin).
Protein binding is approximately 99.5%, primarily to albumin.
Mean apparent volume of distribution is 47 L (approximately 0.6 L/kg), indicating extensive tissue distribution.
Volume of distribution is approximately 4.5 L in infants (mean Vd ≈ 0.3 L/kg), indicating distribution primarily in plasma and interstitial fluid.
Absolute bioavailability of the tablet formulation is approximately 16% after a high-fat meal; dispersible tablet bioavailability is comparable when taken with food.
Bioavailability after intramuscular injection is approximately 70-80% (absolute bioavailability not established; relative to IV data).
For Cr Cl 30-50 m L/min: no adjustment required. For Cr Cl <30 m L/min: contraindicated or not recommended due to lack of data. No specific GFR-based dose reduction recommended.
No dosage adjustment required for renal impairment; nirsevimab is a monoclonal antibody not renally cleared.
Child-Pugh A: reduce dose to 7.5 mg daily. Child-Pugh B: reduce dose to 5 mg daily. Child-Pugh C: contraindicated.
No dosage adjustment required for hepatic impairment; nirsevimab is a monoclonal antibody not hepatically metabolized.
For SEGA in TSC: weight-based dosing targeting AUC similar to adult 10 mg/day. Initial dose 2.5 mg/m² once daily, titrate to trough concentration 5-15 ng/m L. For TSC-associated renal angiomyolipoma: not established in pediatric patients.
Neonates and infants weighing <5 kg: 50 mg intramuscular (IM) single dose; infants weighing ≥5 kg: 100 mg IM single dose. Administer during RSV season.
No specific dose adjustment required based on age alone; monitor renal function and dose adjust per renal/hepatic status. Elderly patients may have increased risk of adverse effects such as stomatitis, infections, and metabolic disturbances.
Not indicated for geriatric population; no dosing recommendations available.
There is no FDA black box warning for Afinitor Disperz. However, serious infections, including opportunistic infections, may occur.
No black box warning.
Non-infectious pneumonitis (including interstitial lung disease) has been reported; monitor for symptoms and consider interruption or discontinuation.,Increased risk of infections, including opportunistic infections (e.g., Pneumocystis jirovecii, TB); monitor and treat promptly.,Increased serum creatinine and proteinuria may occur; monitor renal function.,Angioedema, including life-threatening cases, can occur, especially in patients taking ACE inhibitors.,Stomatitis and mouth ulcers are common; manage with topical treatments and dose modification.,Impaired wound healing; use with caution perioperatively.,Increased risk of bleeding, especially in patients with renal angiomyolipoma and TSC.,Fetal harm can occur; advise effective contraception during treatment.
Hypersensitivity reactions including anaphylaxis have been reported.,Use caution in patients with thrombocytopenia or any coagulation disorder due to risk of bleeding from intramuscular injection.
Hypersensitivity to everolimus, sirolimus, or any component of the formulation,Severe hepatic impairment (Child-Pugh class C) (relative contraindication; use with caution in moderate impairment)
History of serious hypersensitivity reaction to nirsevimab or any component of the formulation.
Avoid grapefruit, grapefruit juice, and Seville oranges due to CYP3A4 inhibition. Avoid high-fat meals, as they reduce absorption; take on empty stomach or with light fat-free meal. St. John's wort reduces everolimus levels and should be avoided.
No known food interactions. BEYFORTUS is administered by intramuscular injection and does not interact with dietary components.
Pregnancy Category D. Animal studies show embryotoxicity and fetotoxicity at subtherapeutic doses. First trimester: risk of major malformations. Second/third trimester: risk of fetal growth restriction, oligohydramnios, and spontaneous abortion.
BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental effects were observed in pregnant rabbits or cynomolgus monkeys at doses up to 10 times the human clinical exposure. However, because monoclonal antibodies are transported across the placenta in increasing amounts as pregnancy progresses (especially in the third trimester), potential fetal exposure may occur. Based on limited data, the risk of major birth defects and miscarriage is unknown but expected to be low due to the Ig G1 nature and lack of known teratogenic signal.
No data on excretion in human milk; M/P ratio unknown. Due to potential serious adverse reactions in nursing infants (e.g., immunosuppression), breastfeeding is contraindicated during treatment and for 2 weeks after last dose.
There are no data on the presence of nirsevimab in human milk, effects on the breastfed infant, or effects on milk production. Nirsevimab is a human monoclonal antibody (Ig G1) and is expected to be excreted into human milk in small amounts due to the high molecular weight and limited transfer via the neonatal Fc receptor. The M/P ratio has not been determined. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BEYFORTUS and any potential adverse effects on the breastfed infant from the drug or underlying condition.
No specific dose adjustments established for pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) may reduce exposure; however, due to teratogenicity, use is not recommended unless benefit outweighs risk. Dose adjustments based on therapeutic drug monitoring are not validated.
No dosing adjustments are required for BEYFORTUS during pregnancy. Pregnancy-related physiological changes (e.g., increased plasma volume, altered renal clearance) are not expected to significantly affect the pharmacokinetics of a monoclonal antibody administered intramuscularly, as nirsevimab has a long half-life and is not renally excreted. The standard single dose of 50 mg (for infants <5 kg) or 100 mg (for infants ≥5 kg) is recommended regardless of pregnancy status.
AFINITOR DISPERZ (everolimus) is an m TOR inhibitor; tablets for oral suspension are not interchangeable with regular tablets due to different pharmacokinetics. Monitor for non-infectious pneumonitis, rash, stomatitis, metabolic effects (hyperglycemia, hyperlipidemia), and renal impairment. Dose adjustments required for hepatic impairment and concurrent strong CYP3A4/P-gp inhibitors or inducers. Avoid live vaccines during treatment.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It is administered as a single intramuscular injection, typically 50 mg for infants <5 kg and 100 mg for infants ≥5 kg. It is not a treatment for active RSV infection. It does not interfere with live attenuated vaccines; however, administration with other injectable vaccines at different sites is acceptable. Do not administer to infants with a history of severe hypersensitivity to nirsevimab or any excipients. Efficacy has not been established in infants with a history of RSV infection.
Take exactly as prescribed; do not crush or chew tablets for oral suspension.,Mix dose with water only, do not mix with juice or other liquids.,Avoid grapefruit, grapefruit juice, and Seville oranges during treatment.,Report any new or worsening shortness of breath, cough, or chest pain immediately.,Use effective non-hormonal contraception during and for 8 weeks after last dose.,Avoid live vaccines and close contact with recently vaccinated individuals.,Monitor for mouth sores; use alcohol-free mouthwash and soft toothbrush.,Do not take St. John's wort or strong CYP3A4/P-gp inhibitors/inducers without consulting doctor.
This vaccine is given as a single shot to prevent serious RSV disease in your infant.,It is not a treatment for active RSV infection; if your infant has RSV symptoms, inform the healthcare provider.,Common side effects include injection site reactions, rash, and fever. Contact your provider if these persist or worsen.,Inform the healthcare provider of any allergic reactions or bleeding disorders before administration.,Your infant can still receive other vaccines as scheduled.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AFINITOR DISPERZ vs BEYFORTUS, answered by our medical review team.
AFINITOR DISPERZ is a mTOR Inhibitor Antineoplastic that works by Everolimus is an m TOR inhibitor that binds to FKBP-12, forming a complex that inhibits the m TOR serine-threonine kinase, thereby blocking cell cycle progression, angiogenesis, and cell growth.. BEYFORTUS is a Monoclonal Antibody for RSV Prophylaxis that works by BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AFINITOR DISPERZ and BEYFORTUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AFINITOR DISPERZ is: 10 mg orally once daily for advanced hormone receptor-positive, HER2-negative breast cancer; 10 mg orally once daily for advanced pancreatic neuroendocrine tumors; 10 mg orally once daily for advanced renal cell carcinoma; 7.5 mg orally once daily for subependymal giant cell astrocytoma (SEGA); 5 mg orally once daily for tuberous sclerosis complex (TSC)-associated renal angiomyolipoma.. The standard adult dose of BEYFORTUS is: Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AFINITOR DISPERZ and BEYFORTUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AFINITOR DISPERZ is classified as Category C. Pregnancy Category D. Animal studies show embryotoxicity and fetotoxicity at subtherapeutic doses. First trimester: risk of major malformations. Second/third trimester: risk of fet. BEYFORTUS is classified as Category C. BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproducti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.